

Yngvar Flå, isand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1085018/publications.pdf>

Version: 2024-02-01

27
papers

400
citations

1040056

9
h-index

794594

19
g-index

29
all docs

29
docs citations

29
times ranked

848
citing authors

#	ARTICLE	IF	CITATIONS
1	A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. <i>Journal of Biological Chemistry</i> , 2021, 296, 100179.	3.4	6
2	DNA glycosylase Neil3 regulates vascular smooth muscle cell biology during atherosclerosis development. <i>Atherosclerosis</i> , 2021, 324, 123-132.	0.8	11
3	A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 2477-2488.	2.4	8
4	Superior Graft-versus-Host Disease-Free Relapse-Free Survival in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation with Anti-Thymocyte Globulin (ATG) Compared to Matched Related Donor without ATG. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 621.e1-621.e3.	1.2	2
5	Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor. <i>British Journal of Haematology</i> , 2020, 188, 187-191.	2.5	7
6	A Middle-Aged Man Presenting With Progressive Heart Failure, Myopathy, and Monoclonal Gammopathy of Uncertain Significance. <i>JACC: Case Reports</i> , 2020, 2, 785-789.	0.6	2
7	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	97
8	Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides. <i>Cancers</i> , 2019, 11, 1088.	3.7	11
9	GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. <i>Haematologica</i> , 2019, 104, e229-e229.	3.5	4
10	Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood. <i>Journal of Immunology</i> , 2019, 203, 1571-1578.	0.8	27
11	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 720-727.	2.0	47
12	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degradator, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. <i>Blood</i> , 2019, 134, 232-232.	1.4	17
13	Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2019, 134, 2547-2547.	1.4	5
14	Cost-utility of allogeneic hematopoietic stem cell transplantation in Norway. <i>Bone Marrow Transplantation</i> , 2018, 53, 657-660.	2.4	10
15	GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. <i>Haematologica</i> , 2018, Online ahead of print, haematol.2018.189399.	3.5	4
16	Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use. <i>Blood</i> , 2018, 132, 2718-2718.	1.4	1
17	A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy. <i>Blood</i> , 2018, 132, 1502-1502.	1.4	1
18	Imaging spectrum of central nervous system complications of hematopoietic stem cell and solid organ transplantation. <i>Neuroradiology</i> , 2017, 59, 105-126.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Targeting Integrin $\alpha 4 \beta 7$ in Steroid-Refractory Intestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 172-175.	2.0	42
20	P-067 Vedolizumab in Treatment of Severe Intestinal Graft Versus Host Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S30-S31.	1.9	0
21	Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries. <i>Pediatric Blood and Cancer</i> , 2016, 63, 83-92.	1.5	16
22	Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. <i>Rheumatology</i> , 2016, 55, 1337-1339.	1.9	49
23	Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support. <i>Blood</i> , 2016, 128, 5826-5826.	1.4	0
24	AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome. <i>Blood</i> , 2015, 126, 3798-3798.	1.4	6
25	Acute Myeloid Leukaemia Treatment in Adults in Norway Five Year Survival and Costs. <i>Blood</i> , 2015, 126, 4490-4490.	1.4	1
26	Eltrombopag in Good's Syndrome. <i>Case Reports in Hematology</i> , 2014, 2014, 1-3.	0.4	5
27	The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpccs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival. <i>Blood</i> , 2013, 122, 5517-5517.	1.4	1